Skip to content

Optimal Nutritional Palliation of Obstructed GEJ Cancer

Optimal Nutritional Palliation of Obstructed GEJ Cancer

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06876454
Enrollment
33
Registered
2025-03-14
Start date
2025-07-01
Completion date
2026-12-31
Last updated
2025-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer

Keywords

metastatic, obstructing

Brief summary

The main goal of this trial is to assess whether it's feasible to conduct a larger, full-scale study comparing the use of gastrostomy (g-tubes) and stents in patients with unresectable cancer of the stomach and/or esophagus, and to evaluate their impact on patients' quality of life. Additional objectives include examining the rates of complications, the need for additional treatments, and the total number of hospital days over a three-month period.

Interventions

Feeding gastrostomy tube insertion

DEVICESelf Expanding Metal esophageal Stent

Fully covered SEMS in the esophagus

Sponsors

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

This study is a single centre, prospective, feasibility randomized controlled clinical trial.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged 18 years of age and older who present with an obstructing metastatic or unresectable gastroesophageal cancer.

Exclusion criteria

* Patients under the age of 18 years. * Prior Esophageal Stent or gastrostomy tube

Design outcomes

Primary

MeasureTime frameDescription
FACT-E3 months• Change in FACT-E scores

Secondary

MeasureTime frameDescription
Complications3 months• The rates of grade 1 to 5 complications as per the TSQIC
Crossover3 monthsRate of crossover from initial intervention to comparator arm

Countries

Canada

Contacts

Primary ContactSamantha So, MSc
Samantha.so@lhsc.on.ca15196858500
Backup ContactDeb Lewis, BSc
Deb.Lewis@lhsc.on.ca

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026